CPS Technologies: A Pivot to Scale, But the Market Remains Sceptical
The Expansion Inflection
CPS Technologies, a small-cap pioneer in metal matrix composites and hermetic packaging, is at a turning point. On the second-quarter call, CEO Brian Mackey delivered the long-awaited update on the new manufacturing facility, a project that has dragged over multiple quarters.
I expect we will soon be making a formal announcement regarding a facility that is twice the size of our current location. The specialized operating factors necessary to optimize our production, including power requirements, industrial gas provisions, the floor build-out, et cetera, and all within relatively close proximity to our current locations to maintain our talented employee base expanded the time line for this effort.
The company raised $9.6 million in a secondary offering in May, boosting combined cash and marketable securities to $19.2 million. That war chest is earmarked for the facility build-out, new equipment, and working capital for growth. CFO Christopher Fraser noted: "We are currently very well funded."
The expansion is not a vanity project; it directly addresses a capacity crunch. “We're also glad to note a substantial recovery in gross margins to 14.8% from 8.6% in Q1,” — Brian Mackey, President and Chief Executive Officer · 2026-08-05 said Mackey, a sign that operational efficiency is improving even before the move. The new facility will allow for better production flow and room for additional equipment, which should drive further margin upside as volumes scale.
Margin Recovery and Cost Dynamics
Gross margin improved sharply sequentially, though year-over-year it remains two points lower. The gross margin of 14.8% in Q2 contrasts with the 8.6% of Q1 and the 16.5% of the year-ago quarter, illustrating the volatility that has plagued the company as it ramps capacity and deals with input costs. Management attributed the year-over-year decline to higher material and plating costs, partially offset by better labor and overhead efficiency.
This recovery is a continuation of a long grind. In the March call, then-CFO Chuck Griffith had noted that inventory builds and learning-curve costs were dragging margins. Now, with the new facility on the horizon, the company expects to add capability without disrupting existing production, giving it a shot at approaching the 20-25% margins it has achieved in the past.
Product Portfolio and Demand
Beyond the facility, the story is about a broadening product portfolio. The company's ALMAX material – a high-performance aluminum matrix composite – is gaining traction, and production capacity is being expanded to meet interest from AI, defense, and energy customers. Mackey mentioned "increased interest from a number of industries including energy infrastructure, AI, defense, semiconductors, space."
The tungsten alloy business, developed under a QuickSet injection molding process, is also showing life. "We are now seeing positive market feedback from our offerings of tungsten alloy components," said Mackey, following the first small commercial sale earlier this year. The U.S. Army-funded controlled fragmentation warhead program continues into fall 2027.
On the armor side, HybridTech Armor is returning with contracts expected later this year for U.S. Navy destroyers, via Kinetic Protection. The company also has a 6-month option on the ACV lightweighting program, which opens another path for both ALMAX and armor solutions.
These initiatives are not new – the new facility has been a theme for several quarters, and ALMAX and tungsten have been discussed since 2025. But the convergence of funding, a signed lease, and commercial traction suggests the company is on the cusp of a step change. In the October 2025 call, Mackey noted, "we've got a focused business development effort underway to add to our team" (“that's why we've got a focused business development effort underway to add to our team” — Brian Mackey, President and CEO · 2025-10-30). That effort is now paying off.
Market and Price Action
Despite the operational optimism, the market remains cautious. The stock has fallen 16.7% over the last 90 days, including a 41% drawdown from its May peak, even as the company executes. The full history shows the stock is still 85% below its 2021 blow-off top, and the recent recovery in gross margin and the cash cushion have not convinced investors that the facility move and new products will translate into sustained profitability.
The fundamental case hinges on execution risk: the facility move, qualification of new lines, and the pace of government and commercial orders. If the lease is signed and the build-out goes smoothly, CPS could emerge as a credible player in AI and defense materials. If not, the stock's drawdown may be a warning that the story has over-promised before.
In prior quarters, management had promised a decision on the facility "within a month" (“I think probably I would expect we'll have a decision on this specific facility within maybe a month” — Charles Griffith, Chief Financial Officer · 2026-03-03). That timeline slipped, and the market's skepticism is understandable. But with cash now on hand and a lease "very close," the pending announcement could be the catalyst that changes the narrative.